All members of the Board of Directors and the Supervisory Board of Gedeon Richter Plc donated their one-month remuneration to the doctors and paramedics of the National Ambulance Service (OMSZ), which plays a key role in the fight against the coronavirus epidemic. The donation of a total of HUF 6 million has been transferred to the association that supports the recreation of the Service's employees.

As a Hungarian-based pharmaceutical company, Richter pays special attention to domestic healthcare. Within the framework of its foundations and social responsibility programmes, the Company spends a significant amount of money every year on improving the facilities of Hungarian healthcare institutions and the health of the Hungarian people. In view of the emergency caused by the coronavirus epidemic, all members of Richter's Board of Directors and Supervisory Board have decided to transfer their one-month remuneration to the association that supports the recreation of the Service's employees. 

"All members of Richter's governing bodies share the commitment that our Company has to domestic healthcare and its employees. We feel it is especially important to support those who, in this extraordinary period full of trials and tribulations, are doing their utmost in the frontline in order to protect the health of the Hungarian people in the fight against the coronavirus," said Erik Bogsch, Chairman of the Board of Gedeon Richter Plc about the donation. 

"Paramedics face severe mental and physical strain in the fight against the coronavirus epidemic. We do everything we can to protect their health, and we have already started to create opportunities for rehabilitation and recreation, for which the support offered by Richter Gedeon Plc is invaluable. Thank you very much," said Dr Gábor Csató, Director General of the National Ambulance Service.

 

About Richter

Gedeon Richter Plc (www.richter.hu), headquartered in Budapest, is one of the largest pharmaceutical companies in Central Eastern Europe, which has established direct presence in Western Europe, China and Latin America. With a market capitalisation of EUR 3.6 (USD 4.1) billion at the end of 2019, Richter recorded approximately EUR 1.6 (USD 1.7) billion in consolidated sales that year. The Company's product portfolio covers almost all important therapeutic areas, including gynaecology, the central nervous system and cardiovascular diseases. As a company with the largest R&D centre in Central Eastern Europe, Richter focuses its original research on central nervous system diseases. With its widely acknowledged steroid chemistry expertise, Richter is also a leading player in gynaecology worldwide. The Company devotes significant resources to the development of biosimilar products.

 

Further information:

Zsuzsa Beke:  +36 1 431 4888